Sandoz d.o.o. (Croatia)

Sandoz d.o.o. is a global leader in the field of generic pharmaceutical products and biosimilar medicines, and is part of the Novartis group. Their mission is to discover new ways to improve the quality and prolong the lives of people. Sandoz contributes to society's ability to meet growing healthcare needs by introducing new approaches to ensure the availability of high-quality medicines worldwide. Their global portfolio consists of approximately 1,000 molecules, covering all major therapeutic areas, with sales amounting to $10.1 billion in 2015. Their wide range of products brings significant and lasting savings to patients and customers, ensuring the sustainability of healthcare systems in the face of increasing budget pressures. This also frees up additional resources for innovative medicines. Their products have reached over 500 million patients, and their goal is to increase this number to one billion. Sandoz's main strength lies in their position as a global leader in biosimilar medicines, advanced innovative medicines with expired patents, and antibiotics, which are the foundation of global healthcare systems. They also carry out numerous targeted corporate responsibility programs aimed at increasing the availability of medicines and medical information, as well as providing appropriate education for healthcare professionals.